ArticleMayo Clinic proceedings2009
Impact of asthma controller medications on clinical, economic, and patient-reported outcomes.
Article in Mayo Clinic proceedings, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.PharmacoEconomics · 2018Pooled it
- Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases.PharmacoEconomics · 2016Pooled it
- Effect of Continuous Positive Airway Pressure on Airway Reactivity in Asthma. A Randomized, Sham-controlled Clinical Trial.Annals of the American Thoracic Society · 2016Trial
- Costs of Single Maintenance and Reliever Therapy vs Traditional Therapy for Asthma.JAMA network open · 2026Article
- Improving Asthma Management: Patient-Pharmacist Partnership Program in Enhancing Therapy Adherence.Pharmacy (Basel, Switzerland) · 2022Article
- The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review.Multidisciplinary respiratory medicine · 2021Article
- Overuse of reliever inhalers and associated healthcare utilization of asthma patients.Scientific reports · 2020Article
- The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies.Clinical and translational allergy · 2019Article
- Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.Clinical and translational allergy · 2019Article
- Economic Burden Associated with Receiving Inhaled Corticosteroids with Leukotriene Receptor Antagonists or Long-Acting Beta Agonists as Combination Therapy in Older Adults.Journal of managed care & specialty pharmacy · 2018Article
- Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization.Journal of managed care & specialty pharmacy · 2017Article
- Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.Journal of managed care & specialty pharmacy · 2017Article
- Motivational interviewing for adherence: post-training attitudes and perceptions of physicians who treat asthma patients.Patient preference and adherence · 2017Article
- Antileukotriene Agents Versus Long-Acting Beta-Agonists in Older Adults with Persistent Asthma: A Comparison of Add-On Therapies.Journal of the American Geriatrics Society · 2016Article
- Asthma Controller Medication Adherence, Risk of Exacerbation, and Use of Rescue Agents Among Texas Medicaid Patients with Persistent Asthma.Journal of managed care & specialty pharmacy · 2015Article
- Potential savings from increasing adherence to inhaled corticosteroid therapy in Medicaid-enrolled children.The American journal of managed care · 2015Article
- Nonadherence in difficult asthma - facts, myths, and a time to act.Patient preference and adherence · 2013Article
- The high cost of cancer drugs and what we can do about it.Mayo Clinic proceedings · 2012Article
- Asthma outcomes: composite scores of asthma control.The Journal of allergy and clinical immunology · 2012Review
- Will comparative effectiveness research finally succeed?Biotechnology healthcare · 2012Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo comprehensively evaluate clinical, economic, and patient-reported outcomes associated with various therapeutic classes of asthma controller medications. PATIENTS AND
methodsThis observational study, which used administrative claims data from US commercial health plans, included patients with asthma aged 18 through 64 years who filled a prescription for at least 1 asthma controller medication from September 1, 2003, through August 31, 2005. Outcome metrics included the use of short-acting beta-agonists (SABAs), the use of oral corticosteroids, inpatient (INP)/emergency department (ED) visits, and asthma-related health care costs. A subset of 5000 patients was randomly selected for a survey using the Mini-Asthma Quality of Life Questionnaire, the Work Productivity and Activity Impairment questionnaire, and the Asthma Therapy Assessment Questionnaire.
resultsOf 56,168 eligible patients, 823 returned completed questionnaires. Compared with inhaled corticosteroids (ICSs), leukotriene modifiers (LMs) were associated with lower odds of INP/ED visits (odds ratio [OR], 0.80; P<.001), lower odds of using 6 or more SABA canisters (OR, 0.81; P<.001), and higher annual cost ($193; P<.001). In the subgroup analysis of adherent patients, LMs were associated with higher odds of INP/ED visits (OR, 1.74; P=.04), lower odds of using 6 or more SABA canisters (OR, 0.46; P<.001), and higher annual cost ($235; P<.001). Inhaled corticosteroids and LMs had a comparable impact on all patient-reported outcomes. For combination therapy, ICS plus a long-acting beta-agonist consistently showed at least equivalent or better outcomes in the use of SABAs and oral corticosteroids, the risk of INP/ED visits, cost, asthma control level, quality of life, and impairment in productivity and activity.
conclusionInhaled corticosteroids were associated with a lower risk of INP/ED visits, and a lower cost if adherence was achieved. When adherence cannot be achieved, LMs may be a reasonable alternative. Combination therapy with ICS plus a long-acting beta-agonist was associated with better or equivalent clinical, economic, and patient-reported outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.